Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience.

Published

Journal Article

Tumor-treating fields (TTFields) is a novel antimitotic treatment modality for patients with glioblastoma. To assess response to TTFields, a newly diagnosed patient with glioblastoma underwent diffusion, perfusion and 3D echo-planar spectroscopic imaging prior to initiation of TTFields plus temozolamide (baseline) and at 1- and 2-month follow-up periods. Increased mean diffusivity along with decreased fractional anisotropy and maximum relative cerebral blood volume were noted at 2 months relative to baseline suggesting inhibition of tumor growth and angiogenesis. Additionally, a reduction in choline/creatine was also noted during this period. These preliminary data indicate the potential of physiologic and metabolic MRI in assessing early treatment response to TTFields in combination with temozolamide.

Full Text

Duke Authors

Cited Authors

  • Mohan, S; Chawla, S; Wang, S; Verma, G; Skolnik, A; Brem, S; Peters, KB; Poptani, H

Published Date

  • July 2016

Published In

Volume / Issue

  • 5 / 3

Start / End Page

  • 137 - 144

PubMed ID

  • 27076281

Pubmed Central ID

  • 27076281

Electronic International Standard Serial Number (EISSN)

  • 2045-0915

Digital Object Identifier (DOI)

  • 10.2217/cns-2016-0003

Language

  • eng

Conference Location

  • England